Irritable Bowel Syndrome Treatment Market to Surpass US$ 2,300 Million Threshold by 2025

TheGlobal Irritable Bowel Syndrome Treatment Market by drug type (lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others), medical condition (IBS-constipation and IBS-diarrhea), distribution channel (hospital pharmacies, online pharmacies, and retail pharmacies) and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 726.1 million in 2016 and is projected to exhibit a CAGR of 12.9% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growing prevalence of irritable bowel syndrome associated with lifestyle factors, stress, and increasing number…

Read More

Irritable Bowel Syndrome Treatment Market – Global Industry Insights, Trends, Outlook, and Analysis, 2017–2025

Irritable bowel syndrome (IBS) causes bouts of stomach cramps, diarrhea, bloating or constipation, where irritable bowel syndrome is a common and long-term condition of the digestive systems. The symptoms of irritable bowel syndrome vary according to individuals and can last from few days to a few months at a time. Irritable bowel syndrome is also observed during stress or after eating certain food. Irritable bowel syndrome is a gastrointestinal disorder of the gut that is characterized by colon muscle contractions that mainly affects the large intestine. Irritable bowel syndrome is…

Read More